“…Indeed, there is a general consensus about GBPs behaving as a repair system upon brain injury in both in vitro and in vivo models (Lanznaster et al, 2016;Ribeiro et al, 2016). Accordingly, 1) higher extracellular levels of GBPs but not ABPs are detected in cultured astrocytes upon hypoxic or hypoglycaemic conditions (Ciccarelli et al, 1999) ii) GBPs, especially GUO, interferes with glutamatergic system by preventing glutamate excitotoxicity (Tasca et al, 2004;Lanznaster et al, 2017); iii) GBPs demonstrate anxiolytic, antidepressant and anticonvulsant effects (Tavares et al, 2008;Kovacs et al, 2015;Bettio et al, 2016;Frinchi et al, 2020); iv) GUO administration prevents NMDA-evoked neurotoxicity and apoptosis in hippocampal slices (Molz et al, 2008), inhibits the neurotoxin 6hydroxydopamine (6-OHDA)-mediated apoptosis in a model of Parkinson's disease (Giuliani et al, 2012b), induces neuroprotection in hippocampal slices subjected to oxygen/ glucose deprivation (OGD) and ischemia (Ganzella et al, 2012;Dal-Cim et al, 2013); v) GUO stimulates neural stem cells and astrocyte proliferation (Ciccarelli et al, 2000;Su et al, 2013), as well as neurogenesis (Bau et al, 2005;Decker et al, 2007;Piermartiri et al, 2020); vi) GTP induces differentiation of C2C12 skeletal muscle cells and PC12 cells via Ca 2+ -activated K + channel, upon phospholipase C (PLC)/ inositol triphosphate (IP3)/diacylglycerol (DAG) activation (Gysbers and Rathbone, 1996;Guarnieri, Fanò et al, 2004;Pietrangelo, Fioretti et al, 2006;Mancinelli, Pietrangelo et al, 2012) vii) GUA improves learning and memory formation (Giuliani et al, 2012a;Zuccarini et al, 2018b).…”